Clinical Trial Update: Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) [Phase 3]

View source ↗

Summary

Phase 3 extension study in pediatric relapsing-remitting multiple sclerosis completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• BG00012 (dimethyl fumarate)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: COMPLETED | Results posted: 2019-11-22